Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Analyst Ratings For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024 ↗
ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
3 Biotech Stocks With Skyrocketing Potential: April 2024 ↗
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
News headline image
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts ↗
 
Via Benzinga
News headline image
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review ↗
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
News headline image
How Is The Market Feeling About Intra-Cellular Therapies? ↗
 
Via Benzinga
News headline image
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know ↗
 
Via Benzinga
News headline image
Where Intra-Cellular Therapies Stands With Analysts ↗
 
Via Benzinga
News headline image
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday ↗
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Expert Ratings for Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study ↗
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. 
Via Benzinga
News headline image
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results ↗
Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Intra-Cellular Therapies's Earnings: A Preview ↗
 
Via Benzinga
News headline image
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Analyst Expectations for Intra-Cellular Therapies's Future ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
News headline image
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Analyst Expectations for Intra-Cellular Therapies's Future ↗
 
Via Benzinga
News headline image
Are These Biotechs Ready To Launch? ↗
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
News headline image
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data ↗
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.